Mesoblast has successfully transitioned from a clinical-stage R&D entity to a commercial-stage biotechnology company following the historic FDA approval of Ryoncil (remestemcel-L) in December 2024. The commercial launch has demonstrated strong initial traction, with quarterly net sales reaching approximately US$30.3 million. This commercial cash flow provides a solid foundation to fund its late-stage pipeline, including Revascor for heart failure and rexlemestrocel-L for chronic low back pain, without relying solely on highly dilutive equity raises. While historical dilution and unprofitability remain key concerns, the current commercial inflection point and upcoming regulatory catalysts present a highly favorable risk-reward profile.